Next-generation antibody platform

Our proprietary antibody discovery platform is a core strength upon which we continue to build and improve. Leveraging this platform, we are able to identify rare and broad antibodies and antibody fragments for viral and oncology targets with enhanced selectivity and potency. We then engineer them to modulate interactions with the immune system and optimize key pharmacokinetic properties, for instance half-life, using tools such as artificial intelligence-led protein engineering. 

Specifically, our proprietary artificial intelligence engine, dAIsY™ (data AI structure and antibody), allows us to bring high-quality drug candidates to the clinic more efficiently. dAIsY™ uses a mix of open source and proprietary tools that run in parallel, allowing us to fine tune multiple desirable antibody characteristics simultaneously, ultimately generating lead candidates with the highest potential for clinical development success.  

The platform has already yielded two commercial medicines, sotrovimab¹ for COVID-19, which was developed in just 15 months, and ansuvimab-zykl for Ebola, which has been recognized by the World Health Organization for its impact.

To learn more about diseases we are targeting using our monoclonal antibody platform, click here.

¹ GSK holds a marketing authorization for sotrovimab in the EU, Norway, Iceland, Bahrain, Great Britain (conditional), and Switzerland (conditional). In Japan, a Special Approval in Emergency has been granted. In addition, sotrovimab has a temporary/emergency use authorization in the UAE and Oman.